Serial 98891935
Live / Allowed — Notice of allowance issued (as of 25 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 09 Dec 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98891935
- Mark type
- Design / logo
- Filed
- 09 Dec 2024
- Published for opposition
- 30 Sept 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, for the activation of PKR (pyruvate kinase R), for the activation of PKM2 (pyruvate kinase isozyme M2), and for the prevention and treatment of blood disorders, sickle cell disease, pyruvate kinase deficiency (PKD), beta thalassemia and alpha thalassemia, genetically defined diseases affecting red blood cells, hereditary spherocytosis, hereditary elliptocytosis, dyserythropoiesis, hemolytic anemia, and other anemias
Owner
- Agios Pharmaceuticals, Inc., Cambridge, MA, US
- Agios Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 25 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Sept 2025 — PUBLISHED FOR OPPOSITION
- 24 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Jun 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Jun 2025 — NON-FINAL ACTION E-MAILED
- 22 Jun 2025 — NON-FINAL ACTION WRITTEN
- 22 Jun 2025 — ASSIGNED TO EXAMINER
- 21 Jun 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 21 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 09 Dec 2024 — APPLICATION FILING RECEIPT MAILED